Cancer's greatest survival trick is adaptation — the ability to reroute itself around whatever therapy is thrown at it, emerging stronger from the very treatments meant to destroy it. Researchers at Baylor College of Medicine have developed an experimental compound called CS18 that attempts to answer this ancient cellular cunning not by blocking one escape route, but by dismantling the central switchboard that governs many of them at once. By targeting a protein called TopBP1, CS18 showed the ability to weaken cancer's defenses and restore the effectiveness of drugs that resistant tumors had l